Nuveen AMT-Free Municipal Credit Income Fund
NVGNASDAQTrading Snapshot
- Day Range
- $10.45 – $10.75
- 52-Week Range
- $249.94 – $550.82
- Volume
- $1.71B
- Avg Volume
- $1.72B
- Shares Outstanding
- 13.39B
- Next Earnings
- Nov 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $215M
- Last Q Revenue
- $115M
- P/E Ratio
- 36.4
- P/S Ratio
- 12.4x
- EPS (TTM)
- $13.65
- Dividend Yield
- 2.45%
- Dilution (1yr)
- +0.0%
Why Investors Own NVG
- ✓High-growth profile — revenue up +8.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 49% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Nuveen AMT-Free Municipal Credit Income Fund
NVG
StockOtter · stockotter.spaceAbout Nuveen AMT-Free Municipal Credit Income Fund
A company profile for Nuveen AMT-Free Municipal Credit Income Fund isn’t available yet — check back soon.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
The Fed Rate Hike Just Made These 4 Muni Funds a Smarter Buy Than MUB
The Fed just handed muni bond investors a rare pricing window, but the funds worth buying are not the ones most investors already own.
Nuveen AMT-Free Municipal Credit Income Fund (NYSE:NVG) Share Price Passes Below 200-Day Moving Average – Should You Sell?
Shares of Nuveen AMT-Free Municipal Credit Income Fund (NYSE: NVG - Get Free Report) crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $12.56 and traded as lo
7%+ Yielding Monthly Dividend Machines For Tax-Advantaged Retirement Income
Finding securities that generate high monthly yields is a big part of successful retirement income investing. However, taxes can eat significantly into those earnings power. I detail 2 tax-efficient 7%+ yielding monthly
NervGen Pharma: I Think The Biggest Risks Are Now Behind It
NervGen Pharma remains a Buy, with reduced regulatory, financing, and execution risks following FDA alignment on the Phase 3 RESTORE trial. NGEN's recent $60M capital raise secures funding for its pivotal trial, shifting